A Phase 1 interventional study of LY3009104 and Placebo in Healthy Participants, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-06.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This will be a 2-part, randomized, participant- and investigator-blind study in healthy males and females.
Part A of this study is to determine a safe and tolerable single oral dose of LY3009104 that yields drug exposures slightly exceeding typical exposures anticipated from repeated administration of an efficacious dose to participants. The concentration of the drug in the blood stream will be measured and information about any side effects that may occur will also be collected.
Part B of this study is to evaluate the effect of LY3009104 on the electrical activity of the heart as measured by electrocardiogram (ECG) in relation to placebo following a single oral dose.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo matching LY3009104 tablets in size and appearance will be administered orally in 1 out of 3 study periods in Part A and Part B.
Drug: Placebo
Part A. Single escalating dose of up to 40 milligrams (mg) of LY3009104 administered orally in 2 out of 3 study periods separated by at least a 3 day wash-out period between each dose. Part B. Single dose of LY3009104 determined in Part A administered orally in 1 out of 3 study periods separated by at least a 3 day wash-out period between each period.
Drug: LY3009104
Part B. 400 mg moxifloxacin will be administered orally in 1 out of 3 study periods separated by at least a 3 day wash-out period between each period.
Drug: moxifloxacin
administered orally
Also known as: Baricitinib
Administered orally
Administered orally
Change From Baseline Through 24 Hours Postdose in Population-Corrected QT (QTcP) Interval
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and is calculated from electrocardiogram (ECG) data. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between 2 R waves. Using the population-corrected formula: QTcP = QT/RR\^beta, where beta is the population correction factor computed from a log-linear model (ln) QT = alpha+beta\*ln RR fitted to all Day -1 and Day 1 predose QT and RR measurements in all periods for all participants. Baseline is the average of data collected for 2 hours before dosing on Day 1 of each period \[-2 hours (h), -1.5 h, -1 h, -0.5 h, and 0 h\]. The QTcP interval was not assessed during Part A of the study, as specified in the protocol. The QTcP interval at 1 h, 2 h, and 4 h postdose for moxifloxacin was compared to placebo to establish assay sensitivity.
Time frame: Part B, Periods 1 through 3: Baseline, 1 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, 12 h, and 24 h postdose
Pharmacokinetics: Maximum Concentration (Cmax) of LY3009104
Time frame: Parts A and B, Periods 1 through 3: Predose and 0.5 hours (h), 1 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, 12 h, 24 h, 36 h, 48 h after administration of study drug
Pharmacokinetics: Area Under the Concentration Curve From Time 0 to Infinity [AUC(0-inf)] of LY3009104
Time frame: Parts A and B, Periods 1 through 3: Predose and 0.5 hours (h), 1 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, 12 h, 24 h, 36 h, 48 h after administration of study drug
Number of Participants With 1 or More Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs)
The number of participants with treatment-emergent adverse events (TEAEs) or treatment-emergent SAEs considered by the investigator to be related to study drug is reported. A summary of SAEs and other non-serious AEs regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through study completion and 30-day follow-up
| Milestone | Part A: Placebo, 30 mg LY3009104, 40 mg LY3009104 | Part A: 20 mg LY3009104, 30 mg LY3009104, Placebo | Part A: 20 mg LY3009104, Placebo, 40 mg LY3009104 | Part B: 40 mg LY3009104, Placebo, Moxifloxacin | Part B: Placebo, Moxifloxacin, 40 mg LY3009104 | Part B: Moxifloxacin, 40 mg LY3009104, Placebo | Part B: Moxifloxacin, Placebo, 40 mg LY3009104 | Part B: 40 mg LY3009104, Moxifloxacin, Placebo | Part B: Placebo, 40 mg LY3009104, Moxifloxacin |
|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 8 | 9 | 9 | 9 | 9 | 9 |
| Received at least 1 dose of study drug | 3 | 3 | 3 | 8 | 9 | 9 | 9 | 9 | 9 |
| Completed | 3 | 3 | 2 | 8 | 9 | 9 | 9 | 9 | 9 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Placebo, 30 mg LY3009104, 40 mg LY3009104 | Part A: 20 mg LY3009104, 30 mg LY3009104, Placebo | Part A: 20 mg LY3009104, Placebo, 40 mg LY3009104 | Part B: 40 mg LY3009104, Placebo, Moxifloxacin | Part B: Placebo, Moxifloxacin, 40 mg LY3009104 | Part B: Moxifloxacin, 40 mg LY3009104, Placebo | Part B: Moxifloxacin, Placebo, 40 mg LY3009104 | Part B: 40 mg LY3009104, Moxifloxacin, Placebo | Part B: Placebo, 40 mg LY3009104, Moxifloxacin |
|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 2 | 8 | 9 | 9 | 9 | 9 | 9 |
| Completed | 3 | 3 | 2 | 8 | 9 | 9 | 9 | 8 | 9 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | Part A: Placebo, 30 mg LY3009104, 40 mg LY3009104 | Part A: 20 mg LY3009104, 30 mg LY3009104, Placebo | Part A: 20 mg LY3009104, Placebo, 40 mg LY3009104 | Part B: 40 mg LY3009104, Placebo, Moxifloxacin | Part B: Placebo, Moxifloxacin, 40 mg LY3009104 | Part B: Moxifloxacin, 40 mg LY3009104, Placebo | Part B: Moxifloxacin, Placebo, 40 mg LY3009104 | Part B: 40 mg LY3009104, Moxifloxacin, Placebo | Part B: Placebo, 40 mg LY3009104, Moxifloxacin |
|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 2 | 8 | 9 | 9 | 9 | 8 | 9 |
| Completed | 3 | 3 | 2 | 8 | 9 | 9 | 9 | 8 | 9 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and is calculated from electrocardiogram (ECG) data. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between 2 R waves. Using the population-corrected formula: QTcP = QT/RR\^beta, where beta is the population correction factor computed from a log-linear model (ln) QT = alpha+beta\*ln RR fitted to all Day -1 and Day 1 predose QT and RR measurements in all periods for all participants. Baseline is the average of data collected for 2 hours before dosing on Day 1 of each period \[-2 hours (h), -1.5 h, -1 h, -0.5 h, and 0 h\]. The QTcP interval was not assessed during Part A of the study, as specified in the protocol. The QTcP interval at 1 h, 2 h, and 4 h postdose for moxifloxacin was compared to placebo to establish assay sensitivity.
| milliseconds (msec) | Part B: Placebo | Part B: 40 mg LY3009104 | Part B: Moxifloxacin |
|---|---|---|---|
| 1 h postdose (n=52, 53, 53) | -2.5 ± 4.9 | -2.4 ± 5.0 | 9.7 ± 5.8 |
| 1.5 h postdose (n=52, 53, 53) | -1.7 ± 3.9 | 0.1 ± 5.5 | 9.3 ± 5.8 |
| 2 h postdose (n=52, 53, 53) | -1.4 ± 6.5 | -0.1 ± 5.3 | 9.5 ± 6.9 |
| 3 h postdose (n=52, 53, 53) | -2.8 ± 5.7 | -2.5 ± 4.9 | 9.2 ± 6.2 |
| 4 h postdose (n=52, 53, 53) | -1.3 ± 5.2 | -0.8 ± 6.2 | 9.9 ± 5.5 |
| 6 h postdose (n=51, 53, 53) | -1.3 ± 8.3 | -2.2 ± 8.1 | 5.5 ± 7.3 |
| 12 h postdose (n=52, 52, 52) | -1.0 ± 8.3 | 0.8 ± 6.6 | 5.9 ± 7.6 |
| 24 h postdose (n=52, 53, 53) | -1.6 ± 6.1 | -0.8 ± 6.7 | 3.4 ± 5.5 |
| nanomoles per liter (nmol/L) | Part A: 20 mg LY3009104 | Part A: 30 mg LY3009104 | Part A: 40 mg LY3009104 | Part B: 40 mg LY3009104 |
|---|---|---|---|---|
| Pharmacokinetics: Maximum Concentration (Cmax) of LY3009104 | 578 ± 28 | 734 ± 14 | 1270 ± 13 | 741 ± 33 |
| hours*nanomoles per liter (h*nmol/L) | Part A: 20 mg LY3009104 | Part A: 30 mg LY3009104 | Part A: 40 mg LY3009104 | Part B: 40 mg LY3009104 |
|---|---|---|---|---|
| Pharmacokinetics: Area Under the Concentration Curve From Time 0 to Infinity [AUC(0-inf)] of LY3009104 | 3960 ± 27 | 5480 ± 19 | 8490 ± 14 | 6440 ± 26 |
The number of participants with treatment-emergent adverse events (TEAEs) or treatment-emergent SAEs considered by the investigator to be related to study drug is reported. A summary of SAEs and other non-serious AEs regardless of causality is located in the Reported Adverse Events module.
| Participants | Part A: Placebo | Part A: 20 mg LY3009104 | Part A: 30 mg LY3009104 | Part A: 40 mg LY3009104 | Part B: Placebo | Part B: 40 mg LY3009104 | Part B: Moxifloxacin |
|---|---|---|---|---|---|---|---|
| Drug-Related TEAE | 0 | 0 | 1 | 0 | 5 | 5 | 5 |
| Drug-Related SAE | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Placebo | — | 0/8 (0%) | 2/8 (25%) |
| Part A: 20 mg LY3009104 | — | 0/6 (0%) | 1/6 (16.7%) |
| Part A: 30 mg LY3009104 | — | 0/6 (0%) | 2/6 (33.3%) |
| Part A: 40 mg LY3009104 | — | 0/5 (0%) | 0/5 (0%) |
| Part B: Placebo | — | 0/52 (0%) | 8/52 (15.4%) |
| Part B: 40 mg LY3009104 | — | 0/53 (0%) | 6/53 (11.3%) |
| Part B: Moxifloxacin | — | 0/53 (0%) | 7/53 (13.2%) |
| Event | Part A: Placebo | Part A: 20 mg LY3009104 | Part A: 30 mg LY3009104 | Part A: 40 mg LY3009104 | Part B: Placebo | Part B: 40 mg LY3009104 | Part B: Moxifloxacin |
|---|---|---|---|---|---|---|---|
| Procedural site reactionInjury, poisoning and procedural complications | 0/8 | 1/6 | 0/6 | 0/5 | 0/52 | 0/53 | 0/53 |
| Muscle tightnessMusculoskeletal and connective tissue disorders | 0/8 | 0/6 | 1/6 | 0/5 | 0/52 | 0/53 | 0/53 |
| Muscle twitchingMusculoskeletal and connective tissue disorders | 0/8 | 0/6 | 1/6 | 0/5 | 0/52 | 0/53 | 0/53 |
| HeadacheNervous system disorders | 0/8 | 0/6 | 1/6 | 0/5 | 1/52 | 2/53 | 1/53 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/8 | 0/6 | 1/6 | 0/5 | 1/52 | 0/53 | 0/53 |
| Increased upper airway secretionRespiratory, thoracic and mediastinal disorders | 0/8 | 0/6 | 1/6 | 0/5 | 0/52 | 0/53 | 0/53 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/8 | 0/6 | 1/6 | 0/5 | 1/52 | 0/53 | 0/53 |
| Respiratory tract congestionRespiratory, thoracic and mediastinal disorders | 1/8 | 0/6 | 1/6 | 0/5 | 0/52 | 0/53 | 0/53 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 1/8 | 0/6 | 0/6 | 0/5 | 0/52 | 0/53 | 0/53 |
| DiarrhoeaGastrointestinal disorders | 0/8 | 0/6 | 0/6 | 0/5 | 3/52 | 2/53 | 4/53 |
Participants who received at least 1 dose of LY3009104, moxifloxacin, or placebo and had at least 1 postdose safety assessment.
| Age, Continuous(years) | Part A (LY3009104 or Placebo) | Part B (LY3009104, Moxifloxacin, or Placebo) | Total |
|---|---|---|---|
| Mean | 45.9 ± 15.4 | 39.9 ± 11.3 | 40.8 ± 12.0 |
| Sex: Female, Male(Participants) | Part A (LY3009104 or Placebo) | Part B (LY3009104, Moxifloxacin, or Placebo) | Total |
|---|---|---|---|
| Female | 4 | 10 | 14 |
| Male | 5 | 43 | 48 |
| Ethnicity (NIH/OMB)(Participants) | Part A (LY3009104 or Placebo) | Part B (LY3009104, Moxifloxacin, or Placebo) | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 21 | 24 |
| Not Hispanic or Latino | 6 | 32 | 38 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Part A (LY3009104 or Placebo) | Part B (LY3009104, Moxifloxacin, or Placebo) | Total |
|---|---|---|---|
| Black or African American | 1 | 12 | 13 |
| White | 8 | 39 | 47 |
| More than 1 race | 0 | 2 | 2 |
| Region of Enrollment(Participants) | Part A (LY3009104 or Placebo) | Part B (LY3009104, Moxifloxacin, or Placebo) | Total |
|---|---|---|---|
| United States | 9 | 53 | 62 |
The record gives a start of Feb 2012, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 3 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib